Table 4 |
||||
| LOAEL symptoms of the DBPCFC-positive children | ||||
| Patient | Age (months) | Sex | Amount of CMP (mg) | Symptoms |
| Acute reactions | ||||
| 29 | 7,5 | F | ? | ery |
| 30 | 134 | M | ? | os, nau |
| 35 | 115 | M | 18 | sw |
| 63 | 4 | M | 18 | ery |
| 108 | 42,5 | F | 18 | os, vom, sw |
| 34 | 10 | M | 180 | ery |
| 90 | 26 | F | 360 | ery, ur |
| 42 | 14,5 | M | 540 | ur |
| 93 | 3 | M | 540 | col |
| 6 | 3,5 | M | 720 | ery |
| 107 | 7 | M | 720 | cry, vom |
| 14 | 5,5 | M | 1080 | ery, ur |
| 85 | 5 | M | 1080 | dia |
| 104 | 119 | M | 1080 | ap, nau |
| 47 | 11 | M | 1620 | ery, vom, dysp, whe |
| 54 | 8,5 | F | 1620 | vom |
| 59 | 7,5 | M | 1620 | ery |
| 66 | 24 | F | 1620 | ery |
| 87 | 7 | F | 1620 | ec |
| 95 | 6 | M | 1620 | cry, dia |
| 114 | 11 | F | 1620 | dia, ery, cry, agi |
| 121 | 17 | M | 1620 | ery, ur |
| 123 | 4 | F | 1620 | agi, fp |
| Late reactions | ||||
| 9 | 7,5 | F | 1620 | dia, cry |
| 19 | 12,5 | M | 1620 | sp, ery |
| 21 | 6 | M | 1620 | ec, con |
| 27 | 5,5 | M | 1620 | dysp |
| 32 | 5,5 | M | 1620 | ec, cry |
| 37 | 2,5 | F | 1620 | agi |
| 39 | 5 | F | 1620 | cry |
| 62 | 13 | F | 1620 | col, cry, con |
| 65 | 7 | F | 1620 | con |
| 73 | 7 | M | 1620 | agi, cry, dia |
| 76 | 15,5 | F | 1620 | cry, sp |
| 79 | 7,5 | F | 1620 | vom, cry |
| 86 | 5 | F | 1620 | dia |
| 103 | 4 | M | 1620 | agi |
| 111 | 4,5 | F | 1620 | con |
DBPCFC, double-blinded placebo-controlled food challenge; LOAEL, lowest observed adverse effect level; agi, agitation; ap, abdominal pain; col, colic; con, constipation; cry, crying; dia, diarrhea; dysp, dyspnea; ec, worsening eczema; ery, erythema; fp, feeding problems; itch, itching; nau, nausea; os, oropharyngeal symptoms; sw, swelling; ur, urticaria; vom, vomiting; whe, wheezing; sp, sleeping problems. Amounts of 18, 180, 360, 540, 720, 1080 and 1620 mg CMP correspond with 1, 10, 20, 30, 40, 60 and 90 ml test feeding respectively.
Dambacher et al. Nutrition Journal 2013 12:22 doi:10.1186/1475-2891-12-22
